IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences:
Event: Jefferies London Healthcare Conference
Location: London
One-on-one meetings: Wednesday, November 15, 2023
Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO